Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.


Deubiquitinase (DUB) profiling goes high-throughput

The Kessler group describes a new methodology named ABPP-HT (high-throughput-compatible activity-based protein profiling), implementing a semi-automated proteomic workflow to profile a panel of deubiquitylating enzyme (DUB) inhibitors in cells. This allows direct cellular target engagement of small molecules against cellular DUBs, thereby accelerating DUB drug discovery.

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva

The Bullock Lab at CMD Oxford were delighted to be a part of this review from LUMC Leiden on Fibrodysplasia ossificans progressiva; an ultrarare congenital disease that progresses through intermittent episodes of bone formation at ectopic sites.

Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer’s disease medicines that alleviate the burden of devastating disease.


In collaboration with the Midwood group @KirOxford, the @YueLabOX & @bmarsden19 labs at @CmdOxford have developed a Target Enabling Package for Tenascin-C, a protein upregulated at sites of #inflammation & contributing to #autoimmune diseases #TNC #TEPs

TNC - A TEP for Inflammatory Disorders